ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab
Status:
Completed
Trial end date:
2018-01-23
Target enrollment:
Participant gender:
Summary
Primary Objective:
To compare the effect of alirocumab with placebo on the occurrence of cardiovascular (CV)
events (composite endpoint of coronary heart disease (CHD) death, non-fatal myocardial
infarction (MI), fatal and non-fatal ischemic stroke, unstable angina (UA) requiring
hospitalization) in participants who experienced an acute coronary syndrome (ACS) event 4 to
52 weeks prior to randomization and were treated with evidence-based medical and dietary
management of dyslipidemia.
Secondary Objectives:
- To evaluate the effect of alirocumab on secondary endpoints (any CHD event , major CHD
event, any CV event, composite of all cause mortality/non-fatal MI/non-fatal ischemic
stroke, CHD deaths, CV deaths, all cause mortality).
- To evaluate the safety and tolerability of alirocumab.
- To evaluate the effect of alirocumab on lipid parameters.